

LUGPA Global Prostate Cancer Congress

January 18-21, 2025 - Sun Valley Resort, Sun Valley, Idaho.

DRAFT AGENDA

Saturday January 18, 2025

TIME	SESSION TOPIC
5:00 p.m. - 7:00 p.m.	Meeting Registration/Information
6:00 p.m. - 7:00 p.m.	Networking Reception in the Exhibit Hall

** Dinner on your own (no scheduled event)

Sunday January 19, 2025

TIME	SESSION and TOPICS
6:30 a.m. – 10:30 a.m. 3:30 p.m. - 6:30 p.m.	Meeting Registration/Information
7:00 a.m. - 7:15 a.m.	Welcome and Introductory Remarks E. David Crawford, MD and Scott Sellinger, MD
7:15 a.m. - 8:15 a.m.	Session 1: Men's Health Issues Moderator: Martin Miner, MD State of Art: Male Mortality Martin Miner, MD Cardio Oncology ADT Scott B. Sellinger, MD, FACS Caretaker Burnout Reena Cherry, PA-C Vitamin D and Men's Health Mark Moyad, MD, MPH Noncardiac Side Effects of ADT Jason Hafron, MD Panel Discussion/ Q & A Session 1 Selected Abstracts
8:15 a.m. -9:00 a.m. 9:00 a.m. - 9:15 a.m.	Industry Sponsored Breakfast Symposium Visit the Exhibit Hall
9:15 a.m. 10:30 a.m.	Session 2: Risk Stratified Approach to diagnosing Prostate Cancer Moderator: Sigrid Carlsson, MD, PhD, MPH State of the Art: Prostate Cancer Risk Stratification: The Synergy of PSA, Biomarkers and MRI Sigrid Carlsson, MD, PhD, MPH Urinary Microbiome and its Impact Michael Liss, MD, PhD, MAS, FACS Prostate Cancer Screening, Tools, Techniques and Advanced Biomarkers William Parker, MD Website Approach for Prostate Cancer Markers E. David Crawford, MD Panel Discussion and Challenging Cases Session 2 Selected Abstracts
10:30 a.m. – 3:30 p.m.	Free Time
3:30 p.m. – 4:15 p.m.	Industry Sponsored Mid-Day Symposium (with food and beverages)
4:15 p.m. -5:15 p.m.	Session 3: Role of Genomics and Genetics in Prostate Cancer Moderators: David Morris, MD and Todd Morgan, MD Newly Identified Mutations Associated with Prostate Cancer Risk and Aggressiveness Brian Helfand, MD, PhD Predictive Markers for Radiation Oncology Peter Orio III, DO, MS Precision Oncology: Utilizing Tissue-Based Molecular Markers in Localized Prostate Cancer Sigrid Carlsson, MD, PhD, MPH Radiogenomics and Natural History of MR Visible vs. Invisible Prostate Cancer: Clinical Implications Laurence Klotz, MD, FRCSC Microbiome and Prostate Cancer Michael Liss, MD, PhD, MS Panel Discussion and Q & A

***Please note that speakers and topics are subject to change

	Session 3 Selected Abstracts
5:15 p.m. – 5:45 p.m.	Break in the Exhibit Hall
5:45 p.m.- 6:30 p.m.	Session 4: Health Policy and Political Advocacy Moderator: Scott B. Sellinger, MD, FACS Panel: Evan Goldfischer, MD, Mara Holton, MD, David Albala, MD, and Richard Harris, MD
6:30 p.m. – 6:45 p.m.	Conclusion and Highlights of the Next Day E. David Crawford, MD and Scott Sellinger, MD, FACS
6:45 p.m. – 8:45 p.m.	Social Activity – Bowling (with food and beverages)

Monday January 20, 2025

TIME	SESSION TOPIC
6:30 a.m. – 10:30 a.m. 3:30 p.m. - 6:45 p.m.	Meeting Registration/Information
7:00 a.m. - 8:00 a.m.	Session 5: Molecular Targeted Imaging Moderator: Phillip Koo, MD Predictive Value of PSMA PET in Prostate Cancer Amir Iravani, MD Expanded Applications for PSMA PET in Prostate Cancer Phillip Koo, MD Value of Integration of PSMA PET into a Urology Practice David Albala, MD High resolution micro ultrasound: Complementary to MRI, or a replacement for MRI Laurence Klotz, MD, FRCSC Panel Discussion/ Q & A Session 5 Selected Abstracts
8:00 a.m. – 8:45 a.m. 8:45 a.m. – 9: 15 a.m.	Industry Sponsored Breakfast Symposium Visit the Exhibit Hall
9:15 a.m. -10:15 a.m.	Session 6: Localized Prostate Cancer Moderator: E. David Crawford, MD Novel focal treatments for prostate cancer Izak Faiena The Role of Radiation Oncology Peter Orio III, DO, MS The Future Role of Telesurgery Dave Albala, MD Navigating Treatment Choices: Active Surveillance vs. Focal vs. Radical Treatment for intermediate risk prostate cancer Brian Helfand, MD, PhD Panel Discussion/Q & A Session 6 Selected Abstracts
10:30 a.m. – 3:30 p.m.	-Free Time
3:30 p.m. – 4:15 p.m.	Industry Sponsored Mid-Day Symposium (with food and beverages) Sponsored by: Johnson & Johnson
4:15 p.m. -5:30 p.m.	Session 7: Advanced Prostate Cancer Moderator: Scott B. Sellinger, MD, FACS State of the Art: mHSPC, mCRPC, roles of PARP-I Maha Hussain, MD, FASCO Using germline genetics to identify men at risk of side effects from ADT Brian Helfand, MD, PhD Management of Non-Metastatic Biochemical Recurrence After Radiation

***Please note that speakers and topics are subject to change

	William Parker, MD Panel Discussion/Q & A Session 7 Selected Abstracts
5:30 p.m. -6:00 p.m.	Break in the Exhibit Hall
6:00 p.m. – 6:40 p.m.	Session 8: Industry: Rapid Fire
7:00 p.m. – 9:30 p.m.	Dinner – Keynote Speaker

Tuesday January 21, 2025

TIME	SESSION TOPIC
6:30 a.m. - 10:30 a.m.	Meeting Registration/Information
7:00 a.m. - 8:00 a.m.	Session 9: Advanced Prostate Cancer Moderator: Dan Petrylak, MD State of Art: mCRPC – Inroads and Improved Outcomes Dan Petrylak, MD Bone Health Paul Siebar, MD Lessons Learned J. Curtis Nickel, MD, FRCSC Panel Discussion/ Q & A Session 9 Selected Abstracts
8:00 a.m. -8:45 a.m.	Industry Sponsored Breakfast Symposium – Sponsored by Astellas Oncology & Pfizer Oncology
9:00 a.m. 9:45 a.m.	Session 10: Preventing and treating side effects Moderator: Jason Hafron, MD Exercise as Part of the Prevention and Treatment of Side Effects Arturo Mendoza-Valdés, MD ADT and ARPIs: Minimizing Side Effects and Maximizing Benefit Laurence Klotz, MD, FRCSC Prevalence and treatment options for ED and MC post prostatectomy and value and efficiency of having a PA integrated into the pathway Jesse Mills, MD Panel Discussion/Q & A Session 10 Selected Abstracts
9:45 a.m. – 10:30 a.m. 10:30 a.m.	Late Breaking Presentations and Abstracts Conclusion/Closing Remarks/Adjourn

***Please note that speakers and topics are subject to change